ALT-2074

DB05631InvestigationalSmall molecule

An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. BXT-51072 has enthusiastic endorsement for treatment in cardiovascular... BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.

Chemical structure of ALT-2074
Primary indication
Investigated for use/treatment in cardiovascular disorders and diabetes mellitus type 1 and 2.Curator reviewed
Formula / weight
C10H13NSe · 226.18 g/mol (avg)
Code names
ALT-2074 · BXT-51072 · SYI-2074

Resolves to

Compound
UNII634U7OUR4RCAS173026-17-0
Structure
InChIKeyFXRYWOJYVGJZLE-UHFFFAOYSA-NSMILESCC1(C)CN[Se]C2=CC=CC=C12
Targets
P35228NOS2

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1Drug interactionStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with ALT-2074, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In